Serum levels of oxidative stress marker malondialdehyde in breast cancer patients in relation to pathohistological factors, estrogen receptors, menopausal status, and age

  • Jasmina Gubaljevic PZU Mediflor, Zivinice, Bosnia and Herzegovina https://orcid.org/0000-0002-3868-1249
  • Nahida Srabović Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina
  • Adlija Jevrić-Čaušević Department of Biochemistry and Clinical Analyses, Faculty of Pharmacy, University of Sarajevo, Bosnia and Herzegovina
  • Adaleta Softić Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina
  • Adi Rifatbegović Clinic for Surgery, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina
  • Jasminka Mujanović-Mustedanagić Polyclinic for Laboratory Diagnostic, University Clinical Centre of Tuzla, Tuzla, Bosnia and Herzegovina
  • Esmeralda Dautović Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina
  • Aida Smajlović Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina
  • Zlata Mujagić Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina
Keywords: breast cancer, oxidative stress, malonaldehide

Abstract

Introduction: The aim of this study was to determine the serum levels of malondialdehyde (MDA) in patients with invasive breast cancer in relation to its serum levels in patients with benign breast disease, and to investigate correlation between MDA serum levels with pathohistological prognostic factors (tumor size, lymph node involvement, and histologic grade [HG]), estrogen receptor (ER) status, and with breast cancer patient’s age and menopausal status.

Methods: A total of 43 with well-documented invasive breast cancer were included in this study: 27 with positive axillary’s lymph nodes, and 16 with negative axillary’s lymph nodes, and 39 patients with findings of benign breast diseases. MDA determination in serum of breast cancer and benign breast disease patients was performed by the fluorimetric method, immunohistochemical staining was performed for ER, and routine pathohistological examination was conducted for pathohistological factors.

Results: MDA serum levels in breast cancer patients were significantly higher than MDA serum levels in benign breast disease patients (p = 0.042). No statistically significant difference between MDA serum levels in breast cancer patients with and without lymph node metastases was found (p = 0.238). No statistically significant correlations between MDA serum levels and tumor size (p = 0.256), HG (p = 0.124), or number of positive lymph nodes (0.113) were found. A statistically significant correlation between serum MDA levels and ages of breast cancer patients with lymph node metastases was found (p = 0.006).

Conclusion: Obtained results support the importance of MDA in the carcinogenesis of breast cancer. According to our findings, serum level of MDA could not be a useful prognostic factor in breast cancer.

Downloads

Download data is not yet available.
Serum levels of oxidative stress marker malondialdehyde (MDA) and its relation to pathohistological parameters, estrogen receptor, menopausal status and age of breast cancer patients
Published
2018-12-18
How to Cite
Gubaljevic, J., Srabović, N., Jevrić-Čaušević, A., Softić, A., Rifatbegović, A., Mujanović-Mustedanagić, J., Dautović, E., Smajlović, A., & Mujagić, Z. (2018). Serum levels of oxidative stress marker malondialdehyde in breast cancer patients in relation to pathohistological factors, estrogen receptors, menopausal status, and age. Journal of Health Sciences, 8(3), 154-161. https://doi.org/10.17532/jhsci.2018.263
Section
Research articles